Efficacy of Geumguesingi-hwan (jinkuishenqi-wan, kinkijinki-gan) in decreasing blood glucose levels in patients with uncomplicated type 2 diabetes: A protocol for systematic review and meta-analysis

Medicine (Baltimore). 2022 Mar 25;101(12):e29079. doi: 10.1097/MD.0000000000029079.

Abstract

Background: The purpose of a systematic review and meta-analysis is to verify the clinical efficacy and safety of Geumguesingihwan for patients with uncomplicated type 2 diabetes.

Methods: The systematic review and meta-analysis will be performed following the guidelines of the National Evidence-based Healthcare Collaborating Agency. We will conduct a systematic search of randomized controlled trials in 8 electronic databases until August 31, 2021.

Results: This study will provide evidence regarding the clinical efficacy of Geumguesingi-hwan from the following 3 perspectives: improving blood glucose level, insulin resistance, and β-cell function. Additionally, we will examine the safety of Geumguesingi-hwan by evaluating the adverse effects.

Conclusions: This study will verify the antidiabetic efficacy and safety of Geumguesingi-hwan in patients with uncomplicated type 2 diabetes.

MeSH terms

  • Blood Glucose*
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Meta-Analysis as Topic
  • Systematic Reviews as Topic

Substances

  • Blood Glucose
  • Hypoglycemic Agents